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Summary
• In the U.S., medical devices are classified into one of three groups based on potential risk to patients
and this plays an important role in determining the appropriate FDA regulatory pathway.
• The three most common regulatory pathways through which the FDA clears or approves devices are:
1) exemption status, 2) 510(k), and 3) premarket approval (PMA).
• Early understanding of likely pathways is essential for planning device design and research strategy.
• All devices with more than a low or non-significant risk potential must be granted clearance, approval,
or an Investigational Device Exemption (IDE) from the FDA prior to use in human subjects.
• Pre-submission, or Q-sub meetings, allow innovators and device companies to meet with the FDA for
free and obtain feedback on the potential pathway and research protocols in an effort to have higher
success with a future formal application.
• Early involvement of a regulatory expert or consultant can lead to a reduction in time to market and
important cost savings.
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Topic Relevance by Time 
Summary 
● In the U.S., medical devices are classified into one of three groups based on potential risk 
to patients and this plays an important role in determining the appropriate FDA regulatory 
pathway. 
● The three most common regulatory pathways through which the FDA clears or approves 
devices are: 1) exemption status, 2) 510(k), and 3) premarket approval (PMA). 
● Early understanding of likely pathways is essential for planning device design and research 
strategy. 
● All devices with more than a low or non-significant risk potential must be granted 
clearance, approval, or an Investigational Device Exemption (IDE) from the FDA prior to 
use in human subjects. 
● Pre-submission, or Q-sub meetings, allow innovators and device companies to meet with 
the FDA for free and obtain feedback on the potential pathway and research protocols in 
an effort to have higher success with a future formal application. 
● Early involvement of a regulatory expert or consultant can lead to a reduction in time to 
market and important cost savings. 
Introduction 
Understanding the fundamentals of FDA regulation is essential for all innovators interested in 
bringing a product or idea forward in the medical device space. Innovators who consider the reg-
ulatory pathway and develop a regulatory strategy earlier in the process of device design or 
development will put themselves at a clear advantage, potentially saving critical time and money 
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that frequently makes the difference between success and failure for a product reaching the market. 
FDA regulation hinges on the invasiveness and risk level of the device, which places it in a specific 
class. Depending on device class, the regulatory process may be straightforward with exempt status 
or more laborious, requiring formal application through premarket clearance using the 510(k) 
process or the premarket approval (PMA) pathway. While the 510(k) pathway is often quicker, 
less costly, and requires less robust, if any, clinical evidence, this pathway depends upon the device 
having a predicate (a similar device with similar proposed indications for use) that has already 
received FDA approval. The average reported costs for a 510(k) is $20 million USD.  Novel or 
high-risk devices usually require the PMA pathway, which often is longer and requires larger clin-
ical trials (which are often randomized controlled trials [RTCs]) at costs exceeding $100 million 
USD, on average. While the basics of FDA regulation are critical for all innovators to learn, navi-
gating the intricacies and complexities of the regulatory landscape almost always requires the 
guidance of experts or consultants, who should be involved as early as possible to improve the 
likelihood of success.  
Background on FDA Regulation 
In 1906, Congress passed the Pure Food and Drugs Act, which initiated the modern regulatory 
functions of what would become the U.S. Food and Drug Administration (FDA) by requiring that 
drugs be held to standards of strength, purity, and quality. After several public health concerns in 
the 1930s, including over 100 deaths (many in children) from the new “wonder drug” elixir 
sulfanilamide, Congress passed the Food, Drug, and Cosmetics Act in 1938 (Office of the 
Commissioner). This act legally mandated that drugs be proven to be safe before being marketed 
to consumers, and the FDA was given authority over inspections and control of advertising, 
including prohibiting false claims. Furthermore, for the first time, the FDA’s control was extended 
to devices, but its power was limited to reviewing devices already on the market for safety, 
efficacy, and proper labeling. This limited role changed the following passage of the Medical 
Device Amendment in 1976, which was triggered, in part, by the Dalkon Shield intrauterine device 
catastrophe, and thus began the FDA’s current era of medical device regulation (Office of the 
Commissioner). 
 
Under this new amendment, the FDA was given authority to ensure the safety and effectiveness of 
medical devices by requiring device manufacturers to register with the FDA and follow quality 
control procedures (Yock et al.). The FDA’s role in device regulation was further expanded by the 
Safe Medical Device Act in 1990, which required post-market surveillance and adverse event 
reporting.  In 1997, the FDA Modernization Act was passed, which attempted to improve the FDA 
review of devices by setting time limits for the steps along the approval process (Adamovich et 
al.; Maisel).   
 
These laws have helped shape the FDA’s role in medical device regulation, which is overseen by 
a branch of the FDA called the Center for Devices and Radiologic Health (CDRH). In 1980, the 
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FDA became part of the Department of Health and Human Services and is currently headquartered 
in Silver Spring, Maryland at the White Oak Federal Center.     
Definition of Medical Device 
In the United States, a medical device is defined by the FDA as: 
 
● “an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or 
other similar or related article, including a component part, or accessory which is … 
intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, 
treatment, or prevention of disease, in man or other animals, or intended to affect the struc-
ture or any function of the body of man or other animals, and which does not achieve any 
of its primary intended purposes through chemical action within or on the body of man or 
other animals and which is not dependent upon being metabolized for the achievement of 
any of its primary intended purposes" (Center for Devices and Radiological Health, “Is The 
Product A Medical Device?”). 
 
In situations when a question arises about whether an innovation or technology is truly a medical 
device, the inventor or company can file a request for designation (RFD) with a proposed recom-
mendation. RFDs are reviewed by the Office of Combination Products (OCP) at the FDA, which 
makes the final decision on the product’s primary mode of action (e.g. if it is a medical device) 
within 60 days of filing and then assigns the product to the appropriate FDA regulatory 
center.  While a lead division will always oversee this process (i.e., Center for Drug Evaluation 
and Research (CDER), Center for Biologics Evaluation and Research (CBER), or CDRH), cross 
consultation within divisions can occur if needed to make the final determination for approval. 
Classification of Medical Devices  
After determining that the product is a medical device, the next step is to correctly classify the 
device based on the FDA’s three-tiered system, which considers the level of risk posed to the 
patient. Proper classification of the device is essential; the device class helps to determine the level 
of FDA review, along with the appropriate regulatory pathway, including the level of control nec-
essary to establish safety and efficacy (Table 1). Class I devices are considered low risk (minimal 
potential harm to patients) and often have a long history of clinical safety and effectiveness (e.g.: 
bandages, surface electrodes, gloves, and surgical instruments). Class II devices pose a moderate 
risk; they are often, but not always, non-invasive and have more complex designs than class I; 
these devices must demonstrate that they can perform as expected without causing harm to patients 
(e.g. surgical sutures and needles, CT scanners or MRI machines, guidewires and angiography 
catheters). Class III devices are considered high risk and are capable of supporting or sustaining 
human life; they are of substantial importance in preventing impairment of human health or are 
new devices or technologies with the potential for high risk of harm or injury to the patient for 
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which no predicate or similar device exists (e.g. heart valves, cardiac stents, spinal cord stimula-
tors, and pacemakers). 
 
Table 1. Risk and Class. 
 
The importance of early and proper classification of a new device cannot be overemphasized, as 
device class will determine the regulatory pathway that, in many ways, determines the time and 
cost necessary (including the type and rigor of preclinical and clinical evidence) to bring the device 
to the market (see the chapter “Strategic planning and costs of FDA Device regulation”). To help 
with this process, one can search the FDA website for the classification of similar products that 
are already on the market; doing so can give hints as to the potential classification and pathway 
required. Additionally, early engagement with a regulatory expert consultant can be invaluable. 
Regulatory Pathways 
Three basic pathways exist for medical devices to obtain FDA marketing approval: 1) exempt 
devices, 2) the 510(k) pathway, and 3) the premarket approval (PMA) pathway (Figure 1). While 
these three regulatory processes are based on the device’s level of risk, there is unfortunately no 
direct match between device class and regulatory pathway. The vast majority (~75%) of class I 
devices, and a small percentage (~10%) of class II devices, qualify for exempt status and do not 
require FDA clearance prior to market entry. These devices do not need proof of safety or efficacy 
because they are low risk. On the other hand, no class III device can receive exempt status.  Despite 
“exemption status,” these class I devices, as well as all class II and III devices, must comply with 
a set of FDA requirements called “general controls.” These requirements require the device com-
pany to register their facility with the FDA, list their device and classification on a submitted form, 
comply with FDA labeling and packaging requirements, and follow the FDA’s quality systems 
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regulation (QSR), which are a set of design and manufacturing guidelines to ensure safety. Not all 
regulations are mandatory for exempt devices. 
 
Figure 1. FDA Approval Pathway. 
 
 
Figure courtesy of Stephen Mckenna 
 
Most class II devices will require the premarket notification 510(k) pathway, which is based on 
the existence of a similar device that has already been FDA-approved and is in use (as described 
below). The PMA pathway is the most intricate and complicated regulatory process, and it is 
required for almost all class III, and some class II, devices. In general, the 510(k) pathway is 
utilized more often than the PMA. In fiscal year 2016, the FDA received 71 PMA submissions, 
compared to 3,204 510(k) submissions. Although PMAs represent only 2% of all premarket 
submissions these numbers reflect a 39% increase in PMA applications, compared to the prior five 
year average; the number of 510(k) applications in 2016 reflect a 16% decrease (“FY 2015 
MDUFA Performance Report”).     
 
A fourth regulatory pathway called the Humanitarian Device Exemption (HDE) can be used for 
certain devices that treat rare diseases (defined as <4,000 patients per year). This process allows 
for the FDA to encourage companies to develop devices for rare disease and is similar to the PMA 
pathway, but it requires less clinical data or proof of effectiveness, because properly powered 
studies for rare diseases could take years to complete in part due to the limited number of patients 
with the rare disease. These devices must first be approved by an IRB before an application is 
submitted. The total review period by the FDA is 75 days after the date of filing of the application. 
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510(k) and de novo 510(k) 
The 510(k) pathway is a premarket submission made by a company or institution to the FDA for 
a medical device (most often class II, occasionally class I or III) that has a predicate device on the 
market already approved by the FDA previously through the 510(k) process. A device that has 
gone through the PMA pathway may not be used as a predicate, unless it has been reclassified 
down to a class II device. The new device must be at least as safe and effective (i.e. “substantially 
equivalent”) to the already approved device. The FDA considers a device substantially equivalent 
when the new device has (Center for Devices and Radiological Health):  
 
a. the same intended use as the predicate and the same technological characteristics as the 
predicate, or 
b. the same intended use as the predicate, different technological characteristics, but does not 
raise new questions of safety and effectiveness. 
 
As defined by the FDA, substantial equivalence “does not mean the new and predicate devices 
must be identical,” but rather they should be similar with “respect to intended use, design, energy 
used or delivered materials, chemical composition, manufacturing process, performance, safety, 
effectiveness, labeling, biocompatibility, standards, and other characteristics, as applicable” 
(Center for Devices and Radiological Health). Ultimately, the FDA will decide if the device 
satisfies substantial equivalence. 
 
A 510(k) must be submitted if a company is introducing a new device to the market for the first 
time, changing the indications for use of a previously cleared device, or significantly modifying a 
previously cleared device. The 510(k) pathway is typically faster and less expensive than the PMA 
pathway and requires less robust clinical evidence. The majority of 510(k) clearances are obtained 
with only bench and preclinical animal studies (see the chapter “Pre-Clinical Animal Models”). 
Currently ~10% of submissions require clinical data, although this number is increasing (Yock et 
al.). In addition to following the requirements for “general controls,” all devices that obtain 510(k) 
premarket notification clearance must also follow a set of FDA requirements called special 
controls. Special controls are usually device-specific and may include patient registries, premarket 
data requirements, performance standards, special labeling requirements, QSR design controls, 
and post-market surveillance. By law, the timeframe for review of a 510(k) submission is 90 days, 
and in fiscal year 2016, this performance requirement was met for 95% of 510(k) submissions 
(“FY 2015 MDUFA Performance Report”). 
 
In addition to the traditional 510(k) pathway, in 1997 the de novo 510(k) pathway was created in 
1997 for devices that do not have the high risks associated with class III, but for which no predicate 
device exists. This pathway can also be used if the FDA determines non-substantial equivalence 
for a device going through the traditional 510(k) process because of a new intended use or different 
technological characteristics that raise questions about safety and effectiveness. The de novo 
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510(k) pathway typically requires higher standards of evidence or data for safety and efficacy than 
a traditional 510(k) but less than what is required for a PMA (Center for Devices and Radiological 
Health, “Requests for Feedback and Meetings for Medical Device Submissions: The Q-
Submission Program”). 
Premarket Approval (PMA) 
PMA is the strictest FDA device regulatory pathway and is required for any device for which there 
is no existing predicate and/or almost all class III devices, which are frequently life-sustaining or 
life-altering (for comparison to 510(k) process see Table 2). The PMA application requires FDA 
scientific, regulatory review and quality system review by a special advisory panel of physicians, 
statisticians, and other topic experts. Approval requires reasonable assurance of safety and effec-
tiveness based on the intended use and clinical evidence. The level of clinical evidence for PMA 
is substantially higher than for a 510(k), and most PMAs require a pivotal study, usually consisting 
of large, randomized, controlled trials.  These studies often take longer to run and cost significantly 
more than those required for 510(k) submissions. Study design and protocol, including the deter-
mination of appropriate endpoints, are critical to support the device’s safety and efficacy for its 
intended use. While costly, PMAs do offer additional protection to innovators, as they cannot be 
used as a predicate in a 510(k), ensuring follow-up products have the same high threshold to cross.  
 
Table 2.  Comparison of PMA vs. 510(k) Pathways in Terms of Challenges and 
Requirements. 
 
The full PMA application includes the proposed labels, compliance with manufacturing and QSR, 
especially in regards to design controls, which are a framework of quality practices and procedures 
that must be followed during the design and development process.  Additionally, the PMA appli-
cation includes preclinical and clinical data (to support the safety and effectiveness of the device), 
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device description, post-market surveillance plan (i.e. post-approval studies), and a full literature 
review and bibliography. While the traditional PMA pathway is used when clinical studies are 
already completed and the application is submitted in its entirety, an alternate pathway called the 
modular PMA exists and is being used more frequently. In this PMA route, the areas and contents 
of the PMA application are broken down into modules or components that are pre-defined, and the 
sponsor submits paperwork for each module as it is completed in real-time. In this way, the com-
pleted PMA is compiled over time, and the FDA can provide feedback as the process is ongoing 
to allow for changes or modifications, reducing the risk and costs associated with a negative 
decision late in the review process (Yock et al.).  
 
The FDA has a 180-day timeframe to complete a PMA review, although at the conclusion of this 
period, the FDA may request additional information. Once the sponsor submits this information, 
the FDA can take an additional 180 days before a decision or before requesting more information. 
Typically, at least two cycles of requests and responses occur before a decision;  the entire process 
may take over a year. The average time to decision by the FDA for PMA applications in fiscal year 
2014 was 330 days (“FY 2015 MDUFA Performance Report”). 
Investigational Device Exemption (IDE)  
Prior to testing a medical device in human subjects as part of a clinical trial to collect safety and 
efficacy data, the FDA requires the device be granted an Investigational Device Exemption (IDE). 
IDEs are usually obtained to support either a future 510(k) or PMA application. Devices that are 
considered to have low or non-significant risks by an Internal Review Board (IRB) at the sponsor-
ing or supporting institution do not require an IDE and can be used in the proposed study without 
FDA involvement. For devices with significant risk, as determined by the IRB, the FDA must first 
approve IDE status and patient counselor forms prior to enrolling patients in clinical trials. The 
IDE application process is substantially less burdensome than the 510(k) and PMA processes, 
although the FDA still requires data to support the safety of the device in humans from laboratory 
experiments, preclinical studies, and any clinical studies from outside the United States (if 
available). A stringent and well thought out clinical study plan is important for an IDE submission, 
and the sponsors can meet with the FDA prior to submitting an application in order to review the 
study protocol. 
Post-Approval Requirements 
Post-approval or post-marketing studies are becoming increasingly common as part of the require-
ments set forth by the FDA when approving a PMA. In general, 510(k) clearances have fewer post-
marketing requirements. PMA post-approval requirements may include on-going clinical trials, 
registry or periodic reporting of safety, reliability, and efficacy of the device as it expands to a 
larger patient population. The FDA requires manufacturers to report all serious adverse reactions 
or events. Furthermore, federal regulations require hospitals, health care professionals, and any 
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user of a medical device to report any patient incidents or adverse events (including serious injury 
or death) involving the device to the manufacturer and the FDA (Van Norman).   
 
The FDA is also in the process of establishing the unique device identifier (UDI) system as part of 
a final rule released in 2013. The final rule requires that device labelers include the UDI on device 
labels and packages. Doing so will allow the FDA to better monitor the distribution and use of all 
medical devices, and improve patient safety and post-market surveillance (Center for Devices and 
Radiological Health, “Unique Device Identification System (UDI System)”). 
Breakthrough Devices Program 
In addition to the standard FDA application process, the FDA has a mechanism for expedited 
review with the aim of reducing the time and cost necessary to move a device from development 
to the market (see the chapter “Strategic planning and costs of FDA Device regulation”). Prior to 
January 2018, several programs offered this service, including the Expedited Access Pathway 
(EAP), the Innovation Pathway, and the Priority Review Program, and existed with various guid-
ance rules and requirements. However, in response to the 21st Century Cure Act, the FDA, at the 
end of 2017 announced the Breakthrough Devices Program (BDP), which supersedes these prior 
programs in order to help patients have more timely access to devices with breakthrough 
technologies while preserving the statutory standards of the regulatory process.  
 
The BDP defines breakthrough devices as those that provide “more effective treatment or diagno-
sis” of life-threatening or irreversibly debilitating diseases and which incorporates breakthrough 
technologies (U.S. FDA Breakthrough). To qualify as “breakthrough technology,” the device must 
have the potential for clinical improvement in diagnosis, treatment, cure, mitigation, or prevention 
of a specific disease or condition. In addition, to meet the criteria of a breakthrough device, there 
must be no approved or cleared alternatives, or the new device must offer “significant advantages” 
over existing approved or cleared alternatives.  
 
The BDP program, like the previous expedited review programs, covers PMA, de novo, and IDE 
applications, and for the first time, expands coverage to qualifying 510(k) applications. In addition 
to undergoing priority review (i.e., placement at the top of the review queue), the benefits of the 
BDP program include earlier communication between the FDA and applicants, more flexibility in 
clinical study designs and the possibility of considering additional post-market data in lieu of 
premarket data, along with expedited manufacturing inspections. Each device in the BDP will be 
assigned to an FDA review team for additional guidance and support. To obtain breakthrough 
device designation, the device sponsor is required to submit a pre-submission application, and the 
FDA will make a decision within 60 days of receipt (Center for Devices and Radiological Health, 
“Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission 
Program”).  
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Conclusion 
The FDA regulation of medical devices protects and promotes public health and patient safety. 
The regulatory pathway is risk-based, and all medical devices can be classified into one of three 
risk classes. Risk class then, for the most part, determines which of the traditional three pathways 
the device will proceed along to obtain FDA clearance or approval. Class I devices are typically 
exempt from clearance, class II devices usually require 510(k) clearance, and class III devices 
almost always require premarket approval. The regulatory strategy also depends on the existence 
of an appropriate predicate device, which can save a device company significant time and money 
if the PMA process can be avoided. Consideration of the regulatory process and engagement with 
a regulatory consultant should begin at the initial phases of device design, as all components of 
device development, especially the research plan, are influenced by class type and regulatory path-
way.   
Resources 
1. Biodesign: The Process of Innovating Medical Technologies 
a. In the book Biodesign: The Process of Innovating Medical Technologies, written by Paul 
Yock, Stefanos Zenios, and Josh Makower, the chapters “4.2 Regulatory Basics” and 
“5.4 Regulatory Strategy” present an excellent overview of regulatory pathways in the 
U.S. and worldwide, especially in the European Union, Canada, China, India, and Japan. 
b. Book available on Amazon: https://www.amazon.com/Biodesign-Process-Innovating-
Medical-
Technologies/dp/110708735X/ref=sr_1_1?s=books&ie=UTF8&qid=1517864373&sr=1-
1&keywords=Biodesign%3A+The+Process+of+Innovating+Medical+Technologies.  
c. Book’s accompanying website: http://ebiodesign.org/.  
2. Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval 
of Medical Devices 
a. The article “Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: 
FDA Approval of Medical Devices” in J Am Coll Cardiol Basic Trans Science provides a 
concise overview of FDA regulatory processes with helpful figures and flowcharts to 
determine the appropriate regulatory pathways for different device types.  
b. Article available here: 
https://www.sciencedirect.com/science/article/pii/S2452302X16300183.  
3. Pre-submissions and Meetings with FDA Staff 
a. The presentation “Pre-submissions and Meetings with FDA Staff” by the U.S. Food and 
Drug Administration is an extremely helpful guide on the pre-submission or Q-sub 
process, explaining the types of meetings and how and when to request them. It also 
includes a list of best practices for meeting with the FDA at the end of the powerpoint. 
b. Presentation available here:  
https://www.fda.gov/media/93740/download. 
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4. Product Classification Database 
a. The “Product Classification Database” hosted by the U.S. Food and Drug Administration 
and the Department of Health and Human Services is an important resource to use early 
during device ideation or development. Users can identify the classifications of current 
devices on the market, and it offers a guide for the likely classification of their new 
device. 
b. Database available here: 
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpcd/classification.cfm. 
5. History of the U.S. Food and Drug Administration 
a. “History,” on the U.S. Food and Drug Administration’s website, gives a detailed history 
of the FDA and the motivation behind its evolution over the years as an overseer of 
medical devices and an advocate for patient safety. 
b. Webpage available here: 
https://www.fda.gov/about-fda/history-fdas-fight-consumer-protection-and-public-health.  
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